This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Exelixis (EXEL) Q2 Earnings & Sales Beat, Cabometyx Shines
by Zacks Equity Research
Exelixis (EXEL) beats on earnings and sales in the second quarter, as lead drug Cabometyx continues momentum.
Is a Beat in Store for Nektar (NKTR) This Earnings Season?
by Zacks Equity Research
The focus will be on Nektar Therapeutics' (NKTR) pipeline progress and launch plans for NKTR-181 when the company reports second-quarter results.
Economic and Earnings Date Deluge
by Zacks Equity Research
Economic and Earnings Date Deluge
Busy Morning for Investors: Trade, Data, Earnings for PFE, MRK, COP & More
by Mark Vickery
Another busy day awaits investors here in the middle of summer: U.S.-China trade talks resume, Personal Income & Spending data is out and Q2 earnings continue their torrent.
Stock Market News For Jul 30, 2019
by Zacks Equity Research
Ongoing U.S. and China trade negotiations and expectations around a Fed rate hike kept benchmarks on a tight leash on Monday.
Mylan (MYL) Beats on Q2 Earnings, Inks Deal with Pfizer
by Zacks Equity Research
Mylan (MYL) gains from merger deal with a Pfizer unit and tops on earnings and sales in Q2.
Pfizer (PFE) Beats on Q2 Earnings, to Merge Upjohn With Mylan
by Zacks Equity Research
Pfizer (PFE) beats estimates for second-quarter earnings but misses on sales. The company also lowers 2019 earnings and sales guidance.
What's in Store for Array BioPharma (ARRY) in Q4 Earnings?
by Zacks Equity Research
Array BioPharma's (ARRY) Braftovi-Mektovi combination therapy is likely to drive fourth-quarter sales.
Pfizer (PFE) Q2 Earnings Top Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 3.90% and -0.44%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Pfizer (PFE) This Earnings Season?
by Zacks Equity Research
While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q2 sales, genericization of some older drugs will hurt the same.
Can Newer Drugs Help Amgen (AMGN) Beat on Earnings in Q2?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products are likely to put pressure on second-quarter sales.
Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment
by Kinjel Shah
AstraZeneca (AZN), Roche (RHHBY), Bristol-Myers (BMY) and Glaxo (GSK) report Q2 results. FDA approves Lilly's (LLY) nasal glucagon to treat severe hypoglycemia.
Bristol-Myers (BMY) Beats on Q2 Earnings & Sales, Raises View
by Zacks Equity Research
Bristol-Myers (BMY) beats both earnings and sales estimates in the second quarter, primarily on robust sales of Opdivo and Eliquis. However, pipeline setbacks are a concern.
Glaxo (GSK) Beats on Q2 Earnings, Shingrix Sales Strong
by Zacks Equity Research
Glaxo (GSK) beats on earnings and sales in the second quarter. Strong growth of vaccine and respiratory portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.
Can Pfizer's Q2 Earnings Help Boost PFE Stock in a Struggling Pharma Market?
by Zachary Stutler
Pfizer Inc. (PFE) is set to report its Q2 earnings results on Tuesday, July 30. Investors are hoping the report can boost PFE stock since it is down over 2% YTD.
What to Expect from Sanofi's (SNY) Q2 Earnings (Revised)
by Mitchell Moore
Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?
What to Expect from Sanofi's (SNY) Q2 Earnings
by Mitchell Moore
Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?
Merck (MRK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive second-quarter sales. However, genericization of key drugs and increased competition are concerns.
Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $42.79, marking a +0.05% move from the previous day.
Q2 Earnings Surprise in the Cards, Healthcare ETFs to Buy
by Sweta Killa
With earnings surprise in cards, the healthcare sector is expected to witness earnings growth of 1.7% in the second quarter, suggesting continued outperformance for healthcare ETFs.
Allergan Announces FDA Acceptance of Glaucoma Candidate NDA
by Zacks Equity Research
The FDA accepts Allergan's (AGN) NDA seeking approval for Bimatoprost SR. A decision is expected in first half of 2020.
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Pfizer, Danaher, Tesla and Cintas
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Pfizer, Danaher, Tesla and Cintas
Should You Pick Up Novartis (NVS) Before Q2 Earnings?
by Mitchell Moore
Novartis AG (NVS) gained 1.1% so far in trading this week. Plus, the Swiss multinational pharmaceutical company has been on a tear since the end of April, up 18.2%. Now let's see what investors should expect heading into its Q2 2019 earnings release on Thursday.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $42.86 in the latest trading session, marking a +0.25% move from the prior day.